Abstract:Background: Cancer-associated fibroblasts (CAFs) in the tumour microenvironment are associated with poor prognosis and chemoresistance in multiple solid tumours. However, there is a lack of universal measures of CAFs in colorectal cancer (CRC). The aim of this study was to assess the utility of a fibroblast-related gene signature (FRGS) for predicting patient outcomes and reveal its relevant mechanism. Methods: The GSE39582 dataset, which includes 316 CRC patients who did not receive adjuvant chemotherapy was used as a discovery cohort to identify the prognostic fibroblast-related genes (FRGs). A total of 1352 CRC patients were divided into one training cohort (GSE39582, n = 461) and two validation cohorts (TCGA, n = 338; meta-validation, n = 553) for the construction of the FRGS and the verification of its prognostic value in stage II/III CRC patients. Functional annotation and analysis were performed to explore the underlying mechanism. The ability of the FRGS to predict immunotherapy response was further tested in a clear cell renal cell carcinoma (ccRCC) cohort. Results: An 11-gene signature that had prognostic value for stage II/III CRC patients in both validation cohorts was developed (TCGA cohort: HR = 1.90, 95% CI 1.16-3.12, P < 0.01; meta-validation cohort: HR = 1.95, 95% CI 1.39-2.73, P < 0.001). A high level of CAFs was correlated with worse prognosis in CRC patients who did not receive adjuvant chemotherapy (HR = 3.63, 95% CI 2.24-5.88, P < 0.001). Importantly, patients in the low-risk group were found to be benefit from chemotherapy (P < 0.01), but not in the high CAF group (P > 0.05). Similar results were found in the TCGA cohort. Integrated with clinical characteristics, the FRGS was confirmed to be an independent prognostic factor in the multivariate analysis after adjustment for tumour TNM stage (GSE39582 cohort: HR = 3.19, 95% CI 1.88-5.41, P < 0.001; TCGA cohort: HR = 5.00, 95% CI 1.58-15.85, P = 0.007; meta-validation cohort: HR = 2.99, 95% CI 1.44-6.21, P = 0.003). Furthermore, the enrichment analysis found that the antitumour immune response was suppressed and the infiltration of CD4 T cells and M1 macrophages was depressed in the high CAF group. The FRGS was also found to have value in predicting for immunotherapy response in the ccRCC cohort. Conclusions: The 11-gene FRGS had independent prognostic value for CRC patients, as well as utility in the prediction of benefit from chemotherapy. CAFs in the tumour microenvironment might have an impact on the prognosis of CRC patients via inhibiting immune response.

IgG Fc Binding Protein (FCGBP) is Down-Regulated in Metastatic Lesions and Predicts Survival in Metastatic Colorectal Cancer Patients

[Igg Fc Binding Protein (FCGBP) As a Prognostic Marker of Low-Grade Glioma and Its Correlation Analysis with Immune Infiltration].

FCGBP Is a Prognostic Biomarker and Associated With Immune Infiltration in Glioma

Fc fragment of IgG binding protein is correlated with immune infiltration levels in hepatocellular carcinoma

Multi-Omics Analyses to Identify FCGBP as a Potential Predictor in Head and Neck Squamous Cell Carcinoma

FCGBP Functions As a Tumor Suppressor Gene in Head and Neck Squamous Cell Carcinoma

Integrated analysis of genes associated with poor prognosis of patients with colorectal cancer liver metastasis

Role of the mucin-like glycoprotein FCGBP in mucosal immunity and cancer

The liver microenvironment orchestrates FGL1-mediated immune escape and progression of metastatic colorectal cancer

Construction of a co-expression network and prediction of metastasis markers in colorectal cancer patients with liver metastasis

Increase in CD4+FOXP3+ Regulatory T Cell Number and Upregulation of the HGF/c-Met Signaling Pathway During the Liver Metastasis of Colorectal Cancer

Construction of a prognostic signature associated with liver metastases for prognosis and immune response prediction in colorectal cancer

Gastric cancer-derived LBP promotes liver metastasis by driving intrahepatic fibrotic pre-metastatic niche formation

Cancer-associated fibroblasts impact the clinical outcome and treatment response in colorectal cancer via immune system modulation: a comprehensive genome-wide analysis

Non-coding RNA-related FCGBP downregulation in head and neck squamous cell carcinoma: a novel biomarker for predicting paclitaxel resistance and immunosuppressive microenvironment

FCGR1A Serves As a Novel Biomarker and Correlates with Immune Infiltration in Four Cancer Types

Immune Checkpoint FGL1 Expression of Circulating Tumor Cells Is Associated With Poor Survival in Curatively Resected Hepatocellular Carcinoma

Expressions of Farnesoid X Receptor and Myeloid Cell Leukemia Sequence 1 Protein Are Associated with Poor Prognosis in Patients with Gallbladder Cancer.

Prognostic value of CD133+ CD54+ CD44+ circulating tumor cells in colorectal cancer with liver metastasis

Immune function status of postoperative patients with colon cancer for predicting liver metastasis

Cancer/testis antigens and clinical risk factors for liver metastasis of colorectal cancer: a predictive panel.